Previous 10 | Next 10 |
BridgeBio Pharma (BBIO -9.8%) has recorded its sharpest intraday loss since January as the company prepares to report topline results from a late-stage trial for Acoramidis. Also called AG10, Acoramidis is its candidate for rare heart disease, transthyretin amyloid cardiomyopathy (ATTR-CM). D...
BridgeBio has been on my radar for over a year now, but the conditions never aligned to start a position. The recent sell-off in the SMID caps has provided an opportunity to buy at a tolerable valuation for the company's prospects. I believe the company's "decentralized" R&D s...
Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings, the consensus holdings were updated, 5 stocks were removed and 5 added from the univ...
BridgeBio Pharma (NASDAQ:BBIO) board granted 9 new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock under the company's inducement equity plan. The Plan was adopted by BridgeBio’s board of directors in November 2019. For fur...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the unive...
Raymond James looks at stocks that may have been unfairly punished by investors looking to realize capital losses. "We have sorted Raymond James coverage universe, and included stocks that have underperformed the S&P 500 (SP500) (NYSEARCA:SPY) by 10% or more in the past two months, and ar...
BridgeBio Pharma (NASDAQ:BBIO) and Helsinn Group have agreed to co-develop and co-commercialize a new therapy for difficult-to-treat tumors. The companies are targeting a first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4). The non-exclusive agreement gives either comp...
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs - BridgeBio and Helsinn have also established a non-exclusive framework agreement to ident...
BridgeBio Pharma (NASDAQ:BBIO) executed a definitive credit facility agreement with a syndicate of lenders for up to $750M in financing which replaces its $100M debt facility with Hercules. Of the total, $450M was funded on Nov.17 while additional $300M will be funded at company's option...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...